Evidence map›Paper›PMID 40621364›Full record

ArticleCureus2025

Survival Following Steroid-Based Therapy in a Case of Penicillin-Induced Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Overlap.

Virgilio Blandon, Miguel Borge

Abstract readCase Reports
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Virgilio BlandonDepartment of Dermatology, Hospital Carlos Roberto Huembes, Managua, NIC.
Miguel BorgeDepartment of Dermatology, Hospital Carlos Roberto Huembes, Managua, NIC.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening mucocutaneous reactions with mortality rates strongly correlated with disease severity. We report the case of a 47-year-old Mestizo man in Nicaragua with penicillin-induced SJS/TEN overlap syndrome (body surface area involvement: 10%-30%, score of toxic epidermal necrolysis, SCORTEN: 4, and predicted mortality: 58%). The patient developed mucosal erosions, hemorrhagic crusting, and disseminated erythematous plaques following exposure to amoxicillin and dicloxacillin (penicillin-class antibiotics). Initial misdiagnoses delayed care, but hospitalization prompted early intravenous dexamethasone, fluid resuscitation, topical corticosteroids, and immediate discontinuation of the offending agents. Epidermal detachment halted within 72 hours, with complete reepithelialization by day 10. Transient hyperglycemia resolved spontaneously, and the patient survived without infections or sequelae, contrasting with the SCORTEN-predicted mortality. This outcome supports early immunomodulation to mitigate cytokine-driven necroptosis, challenging historical concerns about corticosteroid risks. Limitations include the single-case design, absence of histopathology, and lack of human leukocyte antigen allele screening for pharmacogenomic insights. The case underscores the efficacy of prompt corticosteroids in high-risk SJS/TEN linked to penicillin-class drugs, emphasizing drug-specific vigilance and discontinuation. It highlights the need for population-specific SCORTEN calibration, pharmacogenomic integration, and publication of rare cases to enhance regional epidemiological understanding.

Indexed as

dexamethasonedrug eruptionsdrug hypersensitivityglucocorticoidsimmunomodulationpenicillinscortenstevens-johnson syndromestevens-johnson syndrome/toxic epidermal necrolysis overlaptoxic epidermal necrolysis

Identifiers

PMID40621364
PMCPMC12229234

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.